| 发明名称 |
MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS |
| 摘要 |
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function. |
| 申请公布号 |
US2016060335(A1) |
申请公布日期 |
2016.03.03 |
| 申请号 |
US201414779893 |
申请日期 |
2014.03.27 |
| 申请人 |
CEDARS-SINAI MEDICAL CENTER |
发明人 |
Shih David Q.;Targan Stephan R.;Li Dalin;Bilsborough Janine |
| 分类号 |
C07K16/24;G01N33/68;C12N15/113;C12Q1/68;A61K39/395;A61K45/06 |
主分类号 |
C07K16/24 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating fibrosis in a subject, comprising:
providing a composition comprising one or more inhibitors of TL1A-DR3 signaling function; and administering a therapeutically effective dosage of the composition to the subject. |
| 地址 |
Los Angeles CA US |
